Adynxx Inc
OTC:ADYX

Watchlist Manager
Adynxx Inc Logo
Adynxx Inc
OTC:ADYX
Watchlist
Price: 0.0001 USD Market Closed
Market Cap: 5.8 USD

Operating Margin

-1 614.6%
Current
No historical data
Comparison unavailable

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-1 614.6%
=
Operating Income
$-7.4m
/
Revenue
$460k

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-1 614.6%
=
Operating Income
$-7.4m
/
Revenue
$460k

Peer Comparison

Country Company Market Cap Operating
Margin
US
Adynxx Inc
OTC:ADYX
5.8 USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
385.5B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
186.7B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
162.9B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
118.7B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.6B USD
Loading...
AU
CSL Ltd
ASX:CSL
87B AUD
Loading...
NL
argenx SE
XBRU:ARGX
42.8B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
48.8B USD
Loading...

Market Distribution

Lower than 95% of companies in the United States of America
Percentile
5th
Based on 14 112 companies
5th percentile
-1 614.6%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

Adynxx Inc
Glance View

Market Cap
5.8 USD
Industry
Biotechnology

Adynxx, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in San Francisco, California and currently employs 6 full-time employees. The firm is focused on development of non-opioid therapeutics for the treatment of pain and inflammatory diseases. Its AYX platform utilizes a proprietary technology of non-opioid, disease-modifying transcription factor decoys. Its pipeline includes brivoligide and AYX2. Brivoligide product candidate is a potent and selective inhibitor of the transcription factor EGR1. Brivoligide is being developed for the prevention of post-surgical pain. AYX2 is a potent inhibitor of Kruppel-like Factors (KLF) six, nine and 15, transcription factors that maintain neuronal and glial activities involved in pain. AYX2 is being developed for the long-term suppression of chronic pain.

ADYX Intrinsic Value
Not Available
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-1 614.6%
=
Operating Income
$-7.4m
/
Revenue
$460k
How has Operating Margin changed over time?

Over the last 3 years, Adynxx Inc’s Operating Margin has decreased from -181.1% to -1 614.6%. During this period, it reached a low of -1 614.6% on Oct 30, 2019 and a high of -80.4% on Mar 31, 2017.

Back to Top